Enhanced Access to Affordable Medicines on the PBS for Australians

Life-Saving Additions: How the PBS is Expanding Access to Affordable Medications for Australians

For Australians battling high cholesterol, chronic kidney disease, and ovarian cancer, the recent inclusion of several new medications on the Pharmaceutical Benefits Scheme (PBS) brings a beacon of hope. This vital government initiative significantly reduces the financial burden associated with crucial treatments, making them more accessible to those who need them most.

Combating Cholesterol Concerns:

Over 40% of Australians grapple with high cholesterol, a major risk factor for cardiovascular disease. Previously, treatment options were limited, but now, Inclisiran (Leqvio®) joins the PBS lineup. This innovative medication tackles both hereditary and non-hereditary high cholesterol, particularly cases accompanied by atherosclerotic cardiovascular disease. By targeting the PCSK9 protein gene, Inclisiran effectively reduces “bad” cholesterol levels, paving the way for improved cardiovascular health. In 2023, a similar PBS-subsidized treatment benefitted over 10,000 individuals, potentially saving patients upwards of $4,000 annually. This new addition to the PBS is poised to make a similar positive impact.

Empowering Kidney Care:

Chronic kidney disease poses a significant threat to Australians, contributing to a substantial number of hospitalizations and fatalities. Fortunately, the PBS now includes Empagliflozin (Jardiance®), offering a valuable tool for managing this condition. Administered as a convenient once-daily tablet, Jardiance offers multiple benefits, including reducing kidney salt reabsorption and exerting positive cardiovascular and metabolic effects. This multifaceted approach promises improved kidney health outcomes for many Australians. An estimated 14,000 patients annually could potentially benefit from Jardiance’s inclusion, with annual savings exceeding $700 per person without a subsidy.

New Hope for Ovarian Cancer Patients:

Ovarian cancer remains a pressing healthcare concern, claiming the lives of many Australian women. The expanded listing of Niraparib (Zejula®) on the PBS for maintenance therapy provides a critical lifeline for women with HRD-positive advanced ovarian cancer. Early detection of this aggressive cancer can be challenging, as symptoms often mimic those of other conditions, leading to diagnoses at advanced stages. Niraparib’s expanded listing builds upon the recent inclusion of Olaparib, offering a vital new treatment option for approximately 200 women annually. The financial burden associated with Niraparib treatment is significant, with costs reaching around $130,000 per treatment course without government subsidy. Thankfully, the PBS listing ensures affordability, allowing these women to access potentially life-extending treatment.

Unveiling Affordability:

Effective from April 1st, eligible Australians can now obtain these life-saving medications at a significantly reduced cost. The maximum out-of-pocket expense is capped at $31.60 per script, with concession card holders enjoying an even lower cost of $7.70. These substantial reductions in medication costs alleviate the financial strain associated with treatment, allowing patients to focus on their health and well-being.

A Government Committed to Healthcare:

The Australian Minister for Health, Mark Butler, emphasizes the significance of these PBS updates: “Thousands of Australians living with high cholesterol, kidney disease, and ovarian cancer will now have more treatment choices thanks to the Albanese Government.” He further highlights the government’s dedication to affordability and accessibility: “These medicines are subsidised and listed on the PBS so people have better access to the treatments that will help them live better for longer.” Minister Butler reiterated the government’s ongoing commitment to following the recommendations of the independent Pharmaceutical Benefits Advisory Committee and ensuring the continual addition of affordable medications to the PBS.

A Brighter Future for Healthcare Accessibility:

The recent updates to the PBS signify a momentous step forward in ensuring accessible and affordable healthcare for all Australians. By expanding treatment options and subsidizing vital medications, the government demonstrates its unwavering commitment to prioritizing the health and well-being of its citizens. These changes empower Australians battling high cholesterol, chronic kidney disease, and ovarian cancer with the tools they need to manage their conditions effectively and pursue a brighter, healthier future.